Enlivex Therapeutics Stock EBITDA
| ENLV Stock | ILA 415.10 4.10 0.98% |
Enlivex Therapeutics fundamentals help investors to digest information that contributes to Enlivex Therapeutics' financial success or failures. It also enables traders to predict the movement of Enlivex Stock. The fundamental analysis module provides a way to measure Enlivex Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Enlivex Therapeutics stock.
Enlivex |
Enlivex Therapeutics Company EBITDA Analysis
Enlivex Therapeutics' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Enlivex Therapeutics EBITDA | (18.74 M) |
Most of Enlivex Therapeutics' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Enlivex Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
According to the company disclosure, Enlivex Therapeutics reported earnings before interest,tax, depreciation and amortization of (18.74 Million). This is 102.14% lower than that of the Healthcare sector and 118.71% lower than that of the Biotechnology industry. The ebitda for all Israel stocks is 100.48% higher than that of the company.
Enlivex EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Enlivex Therapeutics' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Enlivex Therapeutics could also be used in its relative valuation, which is a method of valuing Enlivex Therapeutics by comparing valuation metrics of similar companies.Enlivex Therapeutics is rated # 5 in ebitda category among its peers.
Enlivex Fundamentals
| Return On Equity | -0.38 | |||
| Return On Asset | -0.19 | |||
| Current Valuation | 147.66 M | |||
| Shares Outstanding | 18.41 M | |||
| Shares Owned By Insiders | 12.19 % | |||
| Shares Owned By Institutions | 9.53 % | |||
| Price To Book | 1.23 X | |||
| EBITDA | (18.74 M) | |||
| Net Income | (14.47 M) | |||
| Cash And Equivalents | 90.6 M | |||
| Cash Per Share | 4.95 X | |||
| Total Debt | 615 K | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 20.29 X | |||
| Book Value Per Share | 3.44 X | |||
| Cash Flow From Operations | (17.54 M) | |||
| Earnings Per Share | (1.07) X | |||
| Number Of Employees | 71 | |||
| Beta | 0.61 | |||
| Market Capitalization | 273.23 M | |||
| Total Asset | 95.15 M | |||
| Net Asset | 95.15 M |
About Enlivex Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Enlivex Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Enlivex Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Enlivex Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Enlivex Stock
When determining whether Enlivex Therapeutics is a strong investment it is important to analyze Enlivex Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Enlivex Therapeutics' future performance. For an informed investment choice regarding Enlivex Stock, refer to the following important reports:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enlivex Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Enlivex Stock refer to our How to Trade Enlivex Stock guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.